Key result
A single positive baseline screen for depression and anxiety in coronary heart disease patients predicted a 71.5% probability of ongoing symptoms over 3 years, along with higher healthcare costs and lower quality of life.
Why the study?
Does a positive baseline screen for depression and anxiety predict ongoing symptoms, higher healthcare costs, and lower quality of life in adults with coronary heart disease?
Cohort (n=803)
Yes
Does a positive baseline screen for depression and anxiety predict ongoing symptoms, higher healthcare costs, and lower quality of life in adults with coronary heart disease?
Absolute Event Rate: 71.5% vs 2.37%
p-value: p=<0.001
A single baseline measure of depression and anxiety in CHD patients strongly predicts persistent symptoms, increased healthcare costs, and reduced physical quality of life over 3 years.
OBJECTIVE: To determine whether a one-off, baseline measure of depression and anxiety in a primary care, coronary heart disease (CHD) population predicts ongoing symptoms, costs, and quality of life across a 3-year follow-up. DESIGN: Longitudinal cohort study. SETTING: 16 General Practice surgeries across South-East London. PARTICIPANTS: 803 adults (70% male, mean age 71 years) contributing up to 7 follow-up points. MAIN OUTCOME MEASURES: Ongoing reporting of symptoms, health care costs, and quality of life. RESULTS: At baseline, 27% of the sample screened positive for symptoms of depression and anxiety, as measured by the Hospital Anxiety and Depression Scale (HADS). The probability of scoring above the cut-off throughout the follow-up was 71.5% (p<0.001) for those screening positive at baseline, and for those screening negative, the probability of scoring below the cut-off throughout the follow-up was 97.6% (p<0.001). Total health care costs were 39% higher during follow-up for those screening positive (p<0.05). Quality of life as measured by the SF-12 was lower on the mental component during follow-up for those screening positive (-0.75, CI -1.53 to 0.03, p = 0.059), and significantly lower on the physical component (-4.99, CI -6.23 to -.376, p<0.001). CONCLUSIONS: A one-off measure for depression and anxiety symptoms in CHD predicts future symptoms, costs, and quality of life over the subsequent three-years. These findings suggest symptoms of depression and anxiety in CHD persist throughout long periods and are detrimental to a patient's quality of life, whilst incurring higher health care costs for primary and secondary care services. Screening for these symptoms at the primary care level is important to identify and manage patients at risk of the negative effects of this comorbidity. Implementation of screening, and possible collaborative care strategies and interventions that help mitigate this risk should be the ongoing focus of researchers and policy-makers.
No takes yet. Share an insight, caveat, or question.
Palacios et al. (2016) conducted a cohort in Coronary Heart Disease (n=803). Positive baseline screen for depression and anxiety (HADS score ≥12) vs. Negative baseline screen for depression and anxiety (HADS score <12) was evaluated on Ongoing symptoms of depression and anxiety (probability of scoring above HADS cut-off throughout 3-year follow-up) (95% CI 61.96-81.04, p=<0.001). A single positive baseline screen for depression and anxiety in coronary heart disease patients predicted a 71.5% probability of ongoing symptoms over 3 years, along with higher healthcare costs and lower quality of life.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: